Camel milk with pegylated interferon alfa-2a and ribavirin for treatment-naive chronic hepatitis C genotype 2 3 : an open-label randomized controlled trial
Joint Authors
Husayni, Sayyid Musa al-Rida
Yusufi, Mahdi
Ghanaei, Omid
Nawras, Muhammad Rida
Zibai, Said
Taghipour, Ali
Source
Iranian Red Crescent Medical Journal
Issue
Vol. 19, Issue 9 (30 Sep. 2017), pp.1-7, 7 p.
Publisher
Publication Date
2017-09-30
Country of Publication
United Arab Emirates
No. of Pages
7
Main Subjects
Abstract EN
Background: Chronic hepatitis C is one of the most important causes of cirrhosis and hepatocellular carcinoma (HCC).
Camel milk (CM) is a new candidate therapy for chronic hepatitis C (CHC).
Objectives: The present study assessed the safety and efficacy of pegylated interferon alfa-2a and ribavirin with CM (CM + Peg IFN/RBV) and without CM (Peg IFN/RBV) in CHC genotype 2/3 infections.
Methods: This study was an open-label, randomized, phase 2 trial.
Sampling strategy and date was computer–generated randomization.
The researchers randomly selected 45 adult patients (ages > 18 years), who were treatment-naive with CHC infection (noncirrhotic) to receive Peg IFN/RBV with standard-dose alone (group A, n = 23), CM+ Peg IFN/RBV: 500 cc orally per day (group B, n = 22) for 24 weeks in Iran.
The primary efficacy outcomes were early virological response (EVR12) and end-of-treatment response (ETR24), the secondary efficacy outcome was sustained virological response (SVR24), and the safety outcomes were adverse events and laboratory tests at end-treatment to assess.
Results: The EVR12 was 60% (12/20), ETR24 90% (18/20), and SVR24 100% (18/18) of CM + Peg IFN/RBV therapy.
The EVR12 was 15% (3/20), ETR24 70% (14/20), and SVR24 rates were 71% (10/14) in Peg IFN/RBV therapy (P < 0.05).
Rates of discontinuation due to adverse events were 8.6% (2/23) in control and no discontinuation in intervention group.
The most common adverse events were fatigue, anemia, and insomnia.
Conclusions: Combination of CM with Peg IFN/RBV for 48 weeks showed significant improvements in the viral response and decreased adverse effects in CHC genotype 2/3 (P < 0.05).
The data of the study supported the CM synergistic antiviral activity of Peg IFN/RBV.
Large clinical trials are needed to confirm the results.
American Psychological Association (APA)
Husayni, Sayyid Musa al-Rida& Zibai, Said& Yusufi, Mahdi& Taghipour, Ali& Ghanaei, Omid& Nawras, Muhammad Rida. 2017. Camel milk with pegylated interferon alfa-2a and ribavirin for treatment-naive chronic hepatitis C genotype 2 3 : an open-label randomized controlled trial. Iranian Red Crescent Medical Journal،Vol. 19, no. 9, pp.1-7.
https://search.emarefa.net/detail/BIM-796198
Modern Language Association (MLA)
Husayni, Sayyid Musa al-Rida…[et al.]. Camel milk with pegylated interferon alfa-2a and ribavirin for treatment-naive chronic hepatitis C genotype 2 3 : an open-label randomized controlled trial. Iranian Red Crescent Medical Journal Vol. 19, no. 9 (Sep. 2017), pp.1-7.
https://search.emarefa.net/detail/BIM-796198
American Medical Association (AMA)
Husayni, Sayyid Musa al-Rida& Zibai, Said& Yusufi, Mahdi& Taghipour, Ali& Ghanaei, Omid& Nawras, Muhammad Rida. Camel milk with pegylated interferon alfa-2a and ribavirin for treatment-naive chronic hepatitis C genotype 2 3 : an open-label randomized controlled trial. Iranian Red Crescent Medical Journal. 2017. Vol. 19, no. 9, pp.1-7.
https://search.emarefa.net/detail/BIM-796198
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references : p. 6-7
Record ID
BIM-796198